Stocks
Anebulo Pharmaceuticals, Inc.ANEB
PNKHealthcareBiotechnology$0.29
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing treatments for acute cannabinoid overdose and other conditions involving the endocannabinoid system. Its lead candidate, ANEB-001, targets the CB1 receptor and is in Phase 2 trials, making it a speculative but focused play in the emerging medical marijuana and drug safety space. Investors track the stock for its regulatory milestones and potential first-mover advantage in a niche therapeutic market.
52W Range: $0.00-$2.77
Congressional Interest in Anebulo Pharmaceuticals, Inc. (ANEB)
No congressional trades have been disclosed for Anebulo Pharmaceuticals, Inc. (ANEB) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ANEB?
No congressional trades found for this stock.